NOW ENROLLING

Research Studies for ages 18-75 to help evaluate investigational treatments for MASH/NASH

About Our Studies

These clinical research studies are evaluating investigational treatments for ages 18-75 with MASH/NASH, with or without cirrhosis. These studies are investigating whether these treatments can halt or reverse liver damage caused by MASH/NASH.

Participation lasts 5 months to 4+ years and includes study-related care, health assessments, and regular monitoring by a clinical team. Eligible participants may include ages 18-75 diagnosed with MASH/NASH who have at least two of the following metabolic risk factors: obesity, high triglycerides, reduced HDL cholesterol, type 2 diabetes, or high blood pressure.

Participants May Receive:

  • Study-related care and monitoring at no cost
  • Care and attention from a dedicated clinical research team
  • Study-related tests and evaluations provided at no charge
  • Compensation for time and travel may be available
  • No health insurance required for participation
  • All study related visits and procedures are scheduled in advance.

You may be able to participate if you:

  • Are 18-75 years of age
  • Have at least two of the following metabolic risk factors: obesity, high triglycerides, reduced HDL cholesterol, type 2 diabetes, or high blood pressure
  • Have MASH or suspected MASH with at least 1 of the following: enhanced liver fibrosis, liver biopsy consistent with suspected MASH, or a FibroScan
  • Are willing to attend scheduled study visits and follow study procedures

About MASH/NASH

Metabolic dysfunction-Associated Steatohepatitis (MASH), previously known as Non-Alcoholic Steatohepatitis (NASH), is a progressive liver disease closely linked to obesity, type 2 diabetes, and metabolic syndrome. It is characterized by excess fat buildup in the liver, along with inflammation and cell damage that can lead to scarring (fibrosis) and, over time, cirrhosis.

Until recently, there were no approved medications specifically for MASH, and management focused primarily on lifestyle changes such as weight loss, diet, and exercise. While some pharmacological options have recently emerged, treatment options remain limited — making ongoing clinical research critical to finding effective therapies for the millions of people living with this condition.

To see if you are eligible, please complete the form to get in touch with the study team.

Your privacy is important to us. By completing the following pre-screener you agree to our Privacy Policy and Terms of Use, and agree that we may retain the personal information you provide and share it with personnel involved in the study, or otherwise as described in the Privacy Policy, and we or our affiliates may contact you by phone using automated technology or pre-recorded voicemail or other means including but not limited to text messages (standard messaging rates may apply) regarding research studies.

1 Questions
2 Contact Info
Are you between the ages of 18 and 75? *
Do you have at least two of the following metabolic risk factors? - Obesity - High triglycerides - Reduced HDL cholesterol - Type 2 diabetes - High blood pressure *
Do you have MASH or suspected MASH with at least 1 of the following? - Enhanced liver fibrosis - Liver biopsy consistent with suspected MASH - A FibroScan (If you are unsure, FibroScan and liver scans can be performed on-site.) *
Do you have a history of excessive alcohol use (more than 15 alcoholic drinks per week, every week, for several years)? *
If you are of childbearing potential, are you willing to use study-required contraception if available? *